
Sign up to save your podcasts
Or


In this JAMA Author Interview, JAMA Interim Executive Editor Greg Curfman, MD, speaks with Mary M. McDermott, MD, professor of medicine at Northwestern University Feinberg School of Medicine, on current therapies for peripheral artery disease and a new clinical trial she directed on the use of telmisartan, an angiotensin receptor blocker, for patients with peripheral artery disease.
Related Content:
Effect of Telmisartan on Walking Performance in Patients With Lower Extremity Peripheral Artery Disease
By JAMA Network4.6
162162 ratings
In this JAMA Author Interview, JAMA Interim Executive Editor Greg Curfman, MD, speaks with Mary M. McDermott, MD, professor of medicine at Northwestern University Feinberg School of Medicine, on current therapies for peripheral artery disease and a new clinical trial she directed on the use of telmisartan, an angiotensin receptor blocker, for patients with peripheral artery disease.
Related Content:
Effect of Telmisartan on Walking Performance in Patients With Lower Extremity Peripheral Artery Disease

38,520 Listeners

43,577 Listeners

27,112 Listeners

134 Listeners

328 Listeners

543 Listeners

705 Listeners

500 Listeners

6,433 Listeners

299 Listeners

265 Listeners

3,377 Listeners

20 Listeners

14 Listeners

7 Listeners

7 Listeners

19 Listeners

29 Listeners

91 Listeners

516 Listeners

362 Listeners

19 Listeners

377 Listeners